A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).

Trial Details

NCT ID
NCT07490613
Phase
PHASE1
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • SHR-3836 administered as multiple doses.
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Age ≥ 18 years, male or female
  • Expected survival ≥ 3 months
  • ECOG performance status 0 or 1
  • Diagnosed with active multiple myeloma per IMWG criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →